• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过全基因组筛选发现OLFML2B是膀胱癌中一种可靠的预后生物标志物：一项基于七个队列的研究

OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts.

作者信息

Lin Jiaxing, Xu Xiao, Li Tianren, Yao Jihang, Yu Meng, Zhu Yuyan, Sun Dan

机构信息

Department of Urology, The First Hospital of China Medical University, Shenyang, China.

Department of Pediatric Intensive Care Unit, The Shengjing Hospital of China Medical University, Shenyang, China.

出版信息

Front Oncol. 2021 Nov 15;11:650678. doi: 10.3389/fonc.2021.650678. eCollection 2021.

DOI:10.3389/fonc.2021.650678
PMID:34868901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8634430/
Abstract

BACKGROUND

Bladder cancer lacks useful and robust prognostic markers to stratify patients at risk. Our study is to identify a robust prognostic marker for bladder cancer.

METHODS

The transcriptome and clinical data of bladder cancer were downloaded from multiple databases. We searched for genes with robust prognosis by Kaplan-Meier analysis of the whole genome. CIBERSORT and TIMER algorithm was used to calculate the degree of immune cell infiltration.

RESULTS

We identified OLFML2B as a robust prognostic marker for bladder cancer in five cohorts. Kaplan-Meier analysis showed that patients with a high level of OLFML2B expression had a poor prognosis. The expression of OLFML2B increased with the increase of stage and grade. We found that patients with high expression of OLFML2B still had a poor prognosis in two small bladder cancer cohorts. OLFML2B also has the prognostic ability in ten other tumors, and the prognosis is poor in high expression. The correlation analysis between OLFML2B and immune cells showed that it was positively correlated with the degree of macrophage infiltration and highly co-expressed with tumor-associated macrophage markers. Finally, the Wound-healing assay and Colony formation assay results showed that the migration and proliferation ability of bladder cancer cell lines decreased after the knockdown of OLFML2B.

CONCLUSIONS

In summary, OLFML2B is a robust risk prognostic marker, and it can help patients with bladder cancer improve individualized treatment.

摘要

背景

膀胱癌缺乏有用且可靠的预后标志物来对高危患者进行分层。我们的研究旨在确定一种可靠的膀胱癌预后标志物。

方法

从多个数据库下载膀胱癌的转录组和临床数据。我们通过对全基因组进行Kaplan-Meier分析来寻找具有可靠预后的基因。使用CIBERSORT和TIMER算法计算免疫细胞浸润程度。

结果

我们在五个队列中确定OLFML2B为膀胱癌的可靠预后标志物。Kaplan-Meier分析表明，OLFML2B表达水平高的患者预后较差。OLFML2B的表达随分期和分级的增加而升高。我们发现，在两个小的膀胱癌队列中，OLFML2B高表达的患者预后仍然较差。OLFML2B在其他十种肿瘤中也具有预后能力，高表达时预后较差。OLFML2B与免疫细胞的相关性分析表明，它与巨噬细胞浸润程度呈正相关，且与肿瘤相关巨噬细胞标志物高度共表达。最后，伤口愈合试验和集落形成试验结果表明，敲低OLFML2B后，膀胱癌细胞系的迁移和增殖能力降低。

结论

综上所述，OLFML2B是一种可靠的风险预后标志物，它有助于膀胱癌患者改善个体化治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/10786db9edef/fonc-11-650678-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/e078d61e7eac/fonc-11-650678-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/2a82ac83236b/fonc-11-650678-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/a52f456b082c/fonc-11-650678-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/3b5794f9c2b7/fonc-11-650678-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/f648c7470b4d/fonc-11-650678-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/81621117f6b7/fonc-11-650678-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/3df80dd241ac/fonc-11-650678-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/c16a7b0ae2dd/fonc-11-650678-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/10786db9edef/fonc-11-650678-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/e078d61e7eac/fonc-11-650678-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/2a82ac83236b/fonc-11-650678-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/a52f456b082c/fonc-11-650678-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/3b5794f9c2b7/fonc-11-650678-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/f648c7470b4d/fonc-11-650678-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/81621117f6b7/fonc-11-650678-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/3df80dd241ac/fonc-11-650678-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/c16a7b0ae2dd/fonc-11-650678-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fe5/8634430/10786db9edef/fonc-11-650678-g009.jpg

相似文献

1
OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts.通过全基因组筛选发现OLFML2B是膀胱癌中一种可靠的预后生物标志物：一项基于七个队列的研究
Front Oncol. 2021 Nov 15;11:650678. doi: 10.3389/fonc.2021.650678. eCollection 2021.
2
Pan-Cancer Analysis of OLFML2B Expression and Its Association With Prognosis and Immune Infiltration.OLFML2B表达的泛癌分析及其与预后和免疫浸润的关联
Front Genet. 2022 Jul 6;13:882794. doi: 10.3389/fgene.2022.882794. eCollection 2022.
3
Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools.基于多种分析工具的胃癌 OLFM2B 过表达的生物信息学研究。
BMC Cancer. 2019 Mar 13;19(1):227. doi: 10.1186/s12885-019-5406-x.
4
A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts.一个强大的11基因预后模型可基于五个队列预测膀胱癌患者的总生存期。
Cancer Cell Int. 2020 Aug 20;20:402. doi: 10.1186/s12935-020-01491-6. eCollection 2020.
5
TRIB3 Promotes the Malignant Progression of Bladder Cancer: An Integrated Analysis of Bioinformatics and Experiments.TRIB3促进膀胱癌的恶性进展：生物信息学与实验的综合分析
Front Genet. 2021 Mar 26;12:649208. doi: 10.3389/fgene.2021.649208. eCollection 2021.
6
Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.鉴定膀胱癌预后相关风险特征，预测患者生存和免疫景观。
J Immunol Res. 2021 Oct 18;2021:3236384. doi: 10.1155/2021/3236384. eCollection 2021.
7
CX3CR1 Acts as a Protective Biomarker in the Tumor Microenvironment of Colorectal Cancer.CX3CR1 在结直肠癌肿瘤微环境中作为一种保护性生物标志物。
Front Immunol. 2022 Jan 24;12:758040. doi: 10.3389/fimmu.2021.758040. eCollection 2021.
8
Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.膀胱癌微环境中与预后相关基因的鉴定——基于 TCGA 数据库。
Biomed Res Int. 2020 Nov 3;2020:9143695. doi: 10.1155/2020/9143695. eCollection 2020.
9
Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.鉴定 NTRK3 作为膀胱癌中与肿瘤突变负担和免疫浸润相关的潜在预后生物标志物。
BMC Cancer. 2021 Apr 24;21(1):458. doi: 10.1186/s12885-021-08229-1.
10
Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.开发和验证一种新型的与脂质代谢相关的基因预后标志物，并为膀胱癌患者找到候选药物。
Lipids Health Dis. 2021 Oct 27;20(1):146. doi: 10.1186/s12944-021-01554-1.

引用本文的文献

1
Mutations in genes encoding innate immune molecules identified in bladder cancer samples as potential biomarkers for immunotherapy with BCG and agonists.在膀胱癌样本中鉴定出的编码天然免疫分子的基因突变，作为卡介苗和激动剂免疫治疗的潜在生物标志物。
Front Urol. 2023 Mar 20;3:984967. doi: 10.3389/fruro.2023.984967. eCollection 2023.
2
Bladder cancer biomarkers.膀胱癌生物标志物
Explor Target Antitumor Ther. 2025 Mar 25;6:1002301. doi: 10.37349/etat.2025.1002301. eCollection 2025.
3
Molecular crosstalk between COVID-19 and Alzheimer's disease using microarray and RNA-seq datasets: A system biology approach.

本文引用的文献

1
Circulating tumor cells in bladder cancer: a new horizon of liquid biopsy for precision medicine.膀胱癌中的循环肿瘤细胞：精准医学液体活检的新视野。
J Basic Clin Physiol Pharmacol. 2021 Sep 27;33(5):525-527. doi: 10.1515/jbcpp-2021-0233. eCollection 2022 Sep 1.
2
A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers.泌尿科癌症中生物标志物评估和认识的 25 年展望。
Urol Oncol. 2021 Sep;39(9):602-617. doi: 10.1016/j.urolonc.2021.06.010. Epub 2021 Jul 24.
3
Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer.
利用微阵列和RNA测序数据集研究COVID-19与阿尔茨海默病之间的分子相互作用：一种系统生物学方法。
Front Med (Lausanne). 2023 Jun 7;10:1151046. doi: 10.3389/fmed.2023.1151046. eCollection 2023.
4
Epigenetic and Tumor Microenvironment for Prognosis of Patients with Gastric Cancer.胃癌患者预后的表观遗传学和肿瘤微环境。
Biomolecules. 2023 Apr 25;13(5):736. doi: 10.3390/biom13050736.
5
Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.Janus 激酶和/或 IFN-γ抑制在原发性噬血细胞性淋巴组织细胞增多症小鼠模型中的细胞和转录影响。
Front Immunol. 2023 Apr 27;14:1137037. doi: 10.3389/fimmu.2023.1137037. eCollection 2023.
6
Matricellular proteins in cutaneous wound healing.皮肤伤口愈合中的基质细胞蛋白
Front Cell Dev Biol. 2022 Nov 24;10:1073320. doi: 10.3389/fcell.2022.1073320. eCollection 2022.
尿液中的液体活检生物标志物：膀胱癌分子诊断与个性化医疗之路。
J Pers Med. 2021 Mar 23;11(3):237. doi: 10.3390/jpm11030237.
4
Development and verification of an immune-related gene pairs prognostic signature in ovarian cancer.卵巢癌免疫相关基因对预后signature 的构建与验证。
J Cell Mol Med. 2021 Mar;25(6):2918-2930. doi: 10.1111/jcmm.16327. Epub 2021 Feb 4.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Integrating Clinical and Genetic Analysis of Perineural Invasion in Head and Neck Squamous Cell Carcinoma.整合头颈部鳞状细胞癌中神经周围侵犯的临床与基因分析
Front Oncol. 2019 May 31;9:434. doi: 10.3389/fonc.2019.00434. eCollection 2019.
7
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets.Metascape 为系统水平数据集的分析提供了面向生物学家的资源。
Nat Commun. 2019 Apr 3;10(1):1523. doi: 10.1038/s41467-019-09234-6.
8
Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools.基于多种分析工具的胃癌 OLFM2B 过表达的生物信息学研究。
BMC Cancer. 2019 Mar 13;19(1):227. doi: 10.1186/s12885-019-5406-x.
9
Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.肌肉浸润性膀胱癌中的肿瘤分子异质性：生物标志物、亚型及对治疗的影响。
Urol Oncol. 2022 Jul;40(7):287-294. doi: 10.1016/j.urolonc.2018.11.015. Epub 2018 Dec 8.
10
CellMarker: a manually curated resource of cell markers in human and mouse.细胞标记物数据库：人类和小鼠细胞标记物的人工整理资源。
Nucleic Acids Res. 2019 Jan 8;47(D1):D721-D728. doi: 10.1093/nar/gky900.